Search Results

You are looking at 51 - 60 of 449 items for :

  • Refine by Access: All x
Clear All
Full access

Neelima N. Nallapaneni, Rajesh Mourya, Vijaya Raj Bhatt, Sakshi Malhotra, Apar Kishor Ganti, and Ketki K. Tendulkar

-lymphocyte-associated antigen-4, leading to tumor cell destruction via enhanced T-cell activation and proliferation. Its use in malignant melanoma is associated with improved overall survival compared with traditional therapies 1 , 2 ; however, activation of CD4 and CD8 T cells

Full access

Andrew J Klink, Bruce Feinberg, Frank Xiaoqing Liu, Sama Ahsan, Damion Nero, and Bartosz Chmielowski

Background: The treatment (tx) landscape for patients (pts) with metastatic melanoma (MM) has changed dramatically from systemic chemotherapy (chemo) to novel therapies, including targeted therapies (TT) and immunotherapies (IO mono- and

Full access

John A. Thompson

The surge in new cases and deaths from melanoma began a few decades ago and continues unabated ( Table 1 ). 1 , 2 In the United States, melanoma is increasing in men more rapidly than any other malignancy and in women more rapidly than any other

Full access

Damon Reed, Ragini Kudchadkar, Jonathan S. Zager, Vernon K. Sondak, and Jane L. Messina

Although melanoma in children remains rare, constituting 1% to 3% of pediatric malignancies, its incidence is increasing. 1 , 2 There is often a low suspicion, with an average time to diagnosis of up to 9 months in reported series. 3 The number

Full access

Benjamin H. Kann, Henry S. Park, Skyler B. Johnson, Veronica L. Chiang, and James B. Yu

More than 20% of patients with cancer will develop brain metastases. 1 Primary malignancies most commonly associated with brain metastases are lung, breast, and gastrointestinal cancers and melanoma, constituting up to 80% of brain metastases. 1

Full access

Daniel G. Coit

I have a clear and vivid recollection of the initial meeting of our NCCN Melanoma Panel 20 years ago. Roughly 25 national experts in melanoma, all from NCI-designated comprehensive cancer centers across the country, including surgeons, medical

Full access

Daniel B. Martin, Sean Silas, Audrey Covner, Paul C. Hendrie, and F. Marc Stewart

of adenopathy in the hundredths ( Figure 2A ). A second challenge is the extensive anatomic descriptions used for some malignancies, such as neuroendocrine tumors and melanoma ( Figure 2B, C ). A third challenge is that many disease groups have

Full access

Anthony J. Olszanski

Oncology Melanoma Program at Fox Chase Cancer Center. “The future will not be just about immunotherapy, but rather the combination of both immunotherapies and cytotoxic therapies,” predicted Dr. Olszanski, who currently serves on the NCCN Guidelines Panel

Full access

Rodger J. Winn

, compliance with standard treatment, and need for emotional support to patients with melanoma . Arch Dermatol 1997 ; 133 : 316 – 321 . 3. Roberts CS Baker F Hann D . Patient-physician communication regarding use of complementary therapies during

Full access

Jarred Burkart, Dwight Owen, Manisha H. Shah, Sherif R. Z. Abdel-Misih, Sameek Roychowdhury, Robert Wesolowski, Sigurdis Haraldsdottir, Julie W. Reeser, Eric Samorodnitsky, Amy Smith, and Bhavana Konda

the colon and lung, papillary thyroid cancer, melanoma, and hairy cell leukemia. 8 In BRAF V600E -mutated melanoma, combined BRAF and MEK inhibition has shown superiority to BRAF monotherapy and has proven to be an effective treatment for metastatic